A landmark study reveals that KMA and LMA selectively identify malignant plasma cells while sparing normal antibody-producing cells, addressing key efficacy and safety gaps in myeloma, AL amyloidosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results